{
    "root": "3027062c-c30a-bcdb-e063-6394a90afcec",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "fluconazole",
    "value": "20250312",
    "ingredients": [
        {
            "name": "ANHYDROUS DIBASIC CALCIUM PHOSPHATE",
            "code": "L11K75P92J"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "FLUCONAZOLE",
            "code": "8VZV102JFY"
        }
    ],
    "indications": "Fluconazole tablets are indicated for the treatment of:\n                  \n                     Vaginal candidiasis (vaginal yeast infections due to\n  \n   Candida).\n \n  \n                     Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of\n  \n   Candidaurinary tract infections, peritonitis, and systemic\n  \n   Candidainfections including candidemia, disseminated candidiasis, and pneumonia.\n \n  \n                     Cryptococcal meningitis. Before prescribing fluconazole tablets for AIDS patients with cryptococcal meningitis, please\n  \n   \n                           see CLINICAL STUDIES\n                        section. Studies comparing fluconazole tablets to amphotericin B in non-HIV infected patients have not been conducted.\n \n  \n                  \n                  Prophylaxis: Fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy.\n                  Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly.",
    "contraindications": "Dosage\n                      \n \n  \n                        and\n                      \n \n  \n                        Administration\n                      \n \n  \n                        in\n                      \n \n  \n                        Adults:\n                      \n\n \n                  \n                     Single \n \n  Dose \n\n \n                  \n                     Vaginal \n \n  candidiasis:The recommended dosage of fluconazole for vaginal candidiasis is 150 mg as a single oral dose.\n\n \n                  \n                     Multiple \n \n  Dose \n\n \n                  SINCE ORAL ABSORPTION IS RAPID AND ALMOST COMPLETE, THE DAILY DOSE OF FLUCONAZOLE IS THE SAME FOR ORAL AND INTRAVENOUS ADMINISTRATION. In general, a loading dose of twice the daily dose is recommended on the first day of therapy to result in plasma concentrations close to steady-state by the second day of therapy.\n                  The daily dose of fluconazole for the treatment of infections other than vaginal candidiasis should be based on the infecting organism and the patient's response to therapy. Treatment should be continued until clinical parameters or laboratory tests indicate that active fungal infection has subsided. An inadequate period of treatment may lead to recurrence of active infection. Patients with AIDS and cryptococcal meningitis or recurrent oropharyngeal candidiasis usually require maintenance therapy to prevent relapse.\n                  \n                     Oropharyngeal \n \n  candidiasis:The recommended dosage of fluconazole for oropharyngeal candidiasis is 200 mg on the first day, followed by 100 mg once daily. Clinical evidence of oropharyngeal candidiasis generally resolves within several days, but treatment should be continued for at least 2 weeks to decrease the likelihood of relapse.\n\n \n                  \n                     Esophageal \n \n  candidiasis:The recommended dosage of fluconazole for esophageal candidiasis is 200 mg on the first day, followed by 100 mg once daily. Doses up to 400 mg/day may be used, based on medical judgment of the patient's response to therapy. Patients with esophageal candidiasis should be treated for a minimum of three weeks and for at least two weeks following resolution of symptoms.\n\n \n                  \n                     Systemic \n \n  Candida \n \n  infections:For systemic\n \n  Candidainfections including candidemia, disseminated candidiasis, and pneumonia, optimal therapeutic dosage and duration of therapy have not been established. In open, noncomparative studies of small numbers of patients, doses of up to 400 mg daily have been used.\n\n \n                  \n                     Urinary \n \n  tract \n \n  infections \n \n  and \n \n  peritonitis:For the treatment of\n \n  Candidaurinary tract infections and peritonitis, daily doses of 50 mg to 200 mg have been used in open, noncomparative studies of small numbers of patients.\n\n \n                  \n                     Cryptococcal \n \n  meningitis:The recommended dosage for treatment of acute cryptococcal meningitis is 400 mg on the first day, followed by 200 mg once daily. A dosage of 400 mg once daily may be used, based on medical judgment of the patient's response to therapy. The recommended duration of treatment for initial therapy of cryptococcal meningitis is 10 to 12 weeks after the cerebrospinal fluid becomes culture negative. The recommended dosage of fluconazole for suppression of relapse of cryptococcal meningitis in patients with AIDS is 200 mg once daily.\n\n \n                  \n                     Prophylaxis \n \n  in \n \n  patients \n \n  undergoing \n \n  bone \n \n  marrow \n \n  transplantation:The recommended fluconazole daily dosage for the prevention of candidiasis in patients undergoing bone marrow transplantation is 400 mg, once daily. Patients who are anticipated to have severe granulocytopenia (less than 500 neutrophils cells/mm\n \n  3) should start fluconazole prophylaxis several days before the anticipated onset of neutropenia, and continue for 7 days after the neutrophil count rises above 1000 cells/mm\n \n  3.\n\n \n                  \n                     \n                        Dosage\n                      \n \n  \n                        and\n                      \n \n  \n                        Administration\n                      \n \n  \n                        in\n                      \n \n  \n                        Pediatric Patients:\n                      \n\n \n                  \n                     Oropharyngeal \n \n  candidiasis:The recommended dosage of fluconazole for oropharyngeal candidiasis in pediatric patients 6 months and older is 6 mg/kg on the first day, followed by 3 mg/kg once daily. Treatment should be administered for at least 2 weeks to decrease the likelihood of relapse.\n\n \n                  \n                     Esophageal \n \n  candidiasis:For the treatment of esophageal candidiasis, the recommended dosage of fluconazole in pediatric patients 6 months and older is 6 mg/kg on the first day, followed by 3 mg/kg once daily. Doses up to 12 mg/kg/day may be used, based on medical judgment of the patient's response to therapy. Patients with esophageal candidiasis should be treated for a minimum of three weeks and for at least 2 weeks following the resolution of symptoms.\n\n \n                  \n                     Systemic Candida infections: The following dosing regimens in Table 6 are recommended for pediatric patients to achieve systemic exposures similar to adults for the treatment of systemic\n \n  Candidainfections, i.e., to maintain an AUC\n \n  0-24between 400 mg*h/L to 800 mg*h/L.\n\n \n                  \n                     Table 6: Recommended Dosing Regimens for the Treatment of Systemic Candida Infections in Pediatric Patients\n                     \n                     \n                     \n                        \n                           \n                              Patient age\n                              \n                           \n                           \n                              Dosing regimen\n                              \n                           \n                        \n                        \n                           3 months and older \n     \n                           \n                           A loading dose of 25-mg/kg on the first day (not to exceed 800 mg) followed by 12-mg/kg once daily (not to exceed 400 mg). \n     \n                           \n                        \n                        \n                           Birth to 3 months postnatal age and gestational age 30 weeks and above \n     \n                           \n                           25-mg/kg on the first day, followed by 12-mg/kg once daily \n     \n                           \n                        \n                        \n                           Birth to 3 months postnatal age and gestational age less than 30 weeks \n     \n                           \n                           25-mg/kg on the first day, followed by 9-mg/kg once daily \n     \n                           \n                        \n                     \n                  \n                  Patients with systemic candidiasis should be treated for a minimum of 3 weeks and for at least 2 weeks following the resolution of symptoms.\n                  \n                     Dosing in Pediatric Patients on ECMO\n                  \n                  The recommended dosage of fluconazole in pediatric patients 3 months and older on ECMO is 35-mg/kg on the first day (not to exceed 800 mg) followed by 12-mg/kg once daily (not to exceed 400 mg).\n                  For patients from birth to 3 months postnatal age, and gestational age less than 30 weeks, a loading dose of 35-mg/kg on the first day followed by 9-mg/kg once daily is recommended. For patients from birth to 3 months postnatal age and gestational age 30 weeks and above, a loading dose of 35-mg/kg on the first day followed by 12-mg/kg once daily is recommended.\n                  Cryptococcal meningitis: For the treatment of acute cryptococcal meningitis, the recommended dosage is 12 mg/kg on the first day, followed by 6 mg/kg once daily. A dosage of 12 mg/kg once daily may be used, based on medical judgment of the patient's response to therapy. The recommended duration of treatment for initial therapy of cryptococcal meningitis is 10 to 12 weeks after the cerebrospinal fluid becomes culture negative. For suppression of relapse of cryptococcal meningitis in pediatric patients with AIDS, the recommended dose of fluconazole is 6 mg/kg once daily.\n                  \n                     \n                        Dosage In Patients With Impaired Renal Function:\n                     \n                  \n                  Fluconazole is cleared primarily by renal excretion as unchanged drug. There is no need to adjust single dose therapy for vaginal candidiasis because of impaired renal function. In patients with impaired renal function who will receive multiple doses of fluconazole, an initial loading dose of 50 mg to 400 mg should be given. After the loading dose, the daily dose (according to indication) should be based on the following summary:\n                  \n                     \n                     \n                     \n                        \n                           \n                              \n                                 Creatinine\n                              \n                              \n                                 Clearance\n                                 (mL/min)\n                              \n                              \n                           \n                           \n                              \n                                 Recommended\n                              \n                              \n                                 Dose (\n                                 %)\n                              \n                              \n                           \n                        \n                        \n                           >50 \n     \n                           \n                           100 \n     \n                           \n                        \n                        \n                           ≤50 (no dialysis) \n     \n                           \n                           50 \n     \n                           \n                        \n                        \n                           Hemodialysis \n     \n                           \n                           100% after each hemodialysis \n     \n                           \n                        \n                     \n                  \n                  Patients on hemodialysis should receive 100% of the recommended dose after each hemodialysis; on non-dialysis days, patients should receive a reduced dose according to their creatinine clearance.\n                  These are suggested dose adjustments based on pharmacokinetics following administration of multiple doses. Further adjustment may be needed depending upon clinical condition.\n                  When serum creatinine is the only measure of renal function available, the following formula (based on sex, weight, and age of the patient) should be used to estimate the creatinine clearance in adults:\n                  Males:       \n \n  Weig\n \n  ht (kg) × (140 – age)\n                  \n                               72 × serum creatinine (mg/100 mL)\n                  Females: 0.85 × above value\n                  Although the pharmacokinetics of fluconazole has not been studied in pediatric patients with renal insufficiency, dosage reduction in pediatric patients with renal insufficiency should parallel that recommended for adults. The following formula may be used to estimate creatinine clearance in pediatric patients:\n                  K ×    \n \n  linear length or height (cm)\n                  \n                           serum creatinine (mg/100 mL)\n                   (Where K=0.55 for pediatric patients older than 1 year and 0.45 for infants.)\n                  \n                     Administration \n\n \n                  Fluconazole tablets are administered orally. Fluconazole tablets can be taken with or without food.",
    "warningsAndPrecautions": "Fluconazole Tablets USP, 100 mg are light pink to pink colored, may be spotted, modified oval shaped, biconvex, uncoated tablets, debossed with '1138' on one side and plain on the other side and are supplied as follows:\n                  \n                  NDC: 70518-2415-00\n                  NDC: 70518-2415-01\n                  NDC: 70518-2415-02\n                  NDC: 70518-2415-03\n                  NDC: 70518-2415-04\n                  \n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 16 in 1 BOTTLE PLASTIC\n                  PACKAGING: 8 in 1 BOTTLE PLASTIC\n                  OUTER PACKAGING: 30 in 1 BOX \n                  INNER PACKAGING: 1 in 1 POUCH \n                  \n                  \n                  \n                  Storage: Store at 20º to 25º C (68º to 77º F) [See USP Controlled Room Temperature].\n                  \n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions": "Fluconazole is contraindicated in patients who have shown hypersensitivity to fluconazole or to any of its excipients. There is no information regarding cross-hypersensitivity between fluconazole and other azole antifungal agents. Caution should be used in prescribing fluconazole to patients with hypersensitivity to other azoles. Coadministration of other drugs known to prolong the QT interval and which are metabolized via the enzyme CYP3A4 such as erythromycin, pimozide, and quinidine are contraindicated in patients receiving fluconazole.\n \n  (\n  \n   See CLINICAL PHARMACOLOGY: Drug Interaction Studies \n \n  and\n \n  \n                        PRECAUTIONS.\n                     )"
}